X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Nicholas Piramal: Lifestyle segment thrust - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Jun 12, 2003

    Nicholas Piramal: Lifestyle segment thrust

    Nicholas Piramal India Limited (NPIL) has reported a healthy growth in topline for FY03 while its bottomline has grown at a more robust rate. In its results announced for FY03, the company has reported a 11% growth in topline while its bottomline has improved by 145%. Improvement in the company's performance in FY03 was mainly on account of better operating margins and lower interest expenses.

    (Rs m) FY02 FY03 Change
    Net Sales 8,662 9,642 11.3%
    Other Income 374 506 35.2%
    Expenditure 7,378 7,863 6.6%
    Operating Profit (EBDIT) 1,284 1,779 38.5%
    Operating Profit Margin (%) 14.8% 18.5%  
    Interest 320 206 -35.7%
    Depreciation 169 235 39.1%
    Profit before Tax 1,170 1,844 57.7%
    Extraordinary items (442) (600)  
    Tax 245 63 -74.2%
    Profit after Tax/(Loss) 482 1,181 144.9%
    Net profit margin (%) 5.6% 12.3%  
    No. of Shares 38.0 38.0  
    Diluted Earnings per share* (Rs) 12.7 31.1  
    P/E Ratio (x)   9.4  
    (* annualised)      

    NPIL has seen strong growth (20%) in its core business of formulations. NPIL has indicated that due to its focus on the lifestyle segment, it has been able to grow faster than the industry average of 6% in the formulations segment. Its acquisition of the ICI's pharma business has helped it further in increasing its exposure to the lifestyle segment. NPIL acquired ICI Limited's pharmaceutical business in FY02. However since this acquisition was done on 26th March 2002, the full effect of the acquisition was seen in FY03.

    The company also acquired Global Bulk Drugs & Fine Chemicals, in FY03. Global Bulk Drugs & Fine Chemicals produces active pharmaceutical ingredients (APIs) and intermediaries and has strong demand for its products in the US and the western European market. ICI Limited on the other hand has a strong exposure to cardiovascular and anaesthetic therapeutic segment. The company also has significant export presence for its bulk drug business. NPIL's growth in topline has also been fueled to an extent by growth in its export revenues. Exports as a percentage of total revenues now stand at 3.4% compared to a negligible amount in FY02.

    The company has also significantly improved its operating margins in FY03. The improvement is to the tune of 370 basis points. This improvement was mainly on account of fall in other expenses. Other expenses as a percentage of total revenues have fallen to 23% compared to 27% in FY02. The company has also significantly benefited from a low interest rate regime. The company has managed to reduce its interest expenses by 35% in FY03. This has improved profitability significantly.

    NPIL's acquisitions in FY03 have resulted in an increase in its depreciation expenses. Depreciation has gone up by 39% in FY03. However the company has seen significant benefits from its acquisition of Global Bulk Drugs & Fine Chemicals. NPIL got a tax benefit of Rs 265 m due to its acquisition. Profit growth however has been restricted due to extraordinary expenses to the tune of Rs 600m, which was mainly comprised of VRS expenses.

    The stock, at Rs 291, is trading at a P/E multiple of 9x its FY03 earnings. The company seems to have benefited from its acquisitions made in the past and recently. Acquisitions have helped it enter into the lucrative and fast growing lifestyle therapeutic segment. Going forward, the company is likely to see growth in its topline from its inorganic growth initiatives and strong growth from its new products in the lifestyle segment. Profitability is also expected to improve due to rationalisation of interest costs and better operating margins.

     

     

    Equitymaster requests your view! Post a comment on "Nicholas Piramal: Lifestyle segment thrust". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    PIRAMAL ENTERPRISES SHARE PRICE


    Aug 18, 2017 (Close)

    TRACK PIRAMAL ENTERPRISES

    • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    MORE ON PIRAMAL ENTERPRISES

    PIRAMAL ENTERPRISES - PFIZER COMPARISON

    Compare Company With Charts

    COMPARE PIRAMAL ENTERPRISES WITH

    MARKET STATS